Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
The study will compare durations of diarrhea among subjects who report to clinic for
 treatment and who receive either:

 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR

 2. a single 600 mg dose of rifaximin daily for 3 days.
Inclusion Criteria:

 -  passage of 3 or more unformed stools in 24 hours plus an additional symptom of enteric
 disease such as abdominal cramps, nausea, vomiting, or fever; and investigator
 verification that an unformed stool has been submitted.

 -  is > 18 years of age

 -  has diarrhea (at least three unformed stools in 24 hrs) plus at least one additional
 sign or symptom of enteric illness

 -  has acute diarrhea less than 1 week's duration

 -  willingness to provide a diarrhea stool sample

 -  willingness to keep a daily diary for 5 days

 -  signed informed consent

 Exclusion Criteria:

 -  fever or bloody diarrhea

 -  has taken predictably effective antibiotics in the past week (e.g. quinolones,
 TMP/SMX, azalide or doxycycline)

 -  is pregnant now, likely to become pregnant, or breast-feeding

 -  has duration of diarrhea of greater than 1 weeks

 -  is allergic to Rifampin or Rifaximin

 -  has a history of significant underlying enteric, pulmonary, cardiac, renal disease, or
 any CNS disorder

 -  is more than moderately dehydrated